Gyre Therapeutics (GYRE) Financials: Revenue & Earnings

GYRE price $7.05 +0.52 +8.03%

Ticker
GYRE
Price
$7.05
Change
+0.52 +8.03%
Market cap ?
$747.97M
Beta ?
4.74
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
58
Value
59
Quality
33
Growth
83

Stocklytics score rationale: value 59, quality 33, growth 83.

Fair value

GYRE fair value $35.42. Price $7.05. Price is 80% below fair value.

Above fair value, and more expensive than usual. A larger premium than on 71% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 17.78M. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 2.0). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 106.03M. Net debt -36.13M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Model uncertainty high for this stock

Compare GYRE

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-06—-0.15—28.40M
2026-08-07-0.12-0.0629.11M26.49M
2026-05-07-0.05-0.0622.52M31.61M
2026-03-12-0.020.0637.20M35.43M
2025-11-070.060.0530.56M32.93M
2025-08-110.020.0326.77M30.80M
2025-05-090.030.0322.06M28.40M
2025-03-170.010.0427.87M23.50M
2024-11-140.01—25.49M113.45M
2024-08-130.01—25.23M113.45M
2024-05-090.03—27.17M—
2024-03-28-1.39-0.6027.15M113.45M
2023-10-26-1.05-0.7532.04M—
2023-08-14-1.05-1.0529.33M—
2023-05-150.15-1.0524.93M400.00K
2023-03-30-0.05-1.57794.00K400.00K
2022-11-23-2.40-1.5029.17M—
2022-08-1524.60-3.6743.85M797.00K
2022-05-09-6.90-6.85794.00K797.00K
2022-03-31-0.65-8.812.44M166.67K
2021-11-12-0.80-9.902.30M675.00K
2021-08-05-0.64-10.431.13M333.33K
2021-05-06-0.79-8.661.47M1.07M
2021-03-04-0.85-12.102.03M2.10M
2020-11-05-0.73-12.94893.00K300.00K
2020-08-06-0.96-5.471.66M7.95M
2020-05-11-0.282.5516.37M15.00M
2020-02-20-1.13-17.32—450.00K
2019-11-07-1.06-17.40—450.00K
2019-08-01-1.15———
2019-05-02-1.26———
2019-03-08-0.91—6.00K—
2018-11-01-0.64———
2018-08-02-0.54———
2018-05-03-0.56—6.00K—
2018-03-19-1.26—318.00K—
2017-11-02-1.34—318.00K—
2017-08-03-2.53—111.00K—
2017-05-11-4.57—271.00K—
2017-03-08-4.68—71.00K—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency Quarterly.

Safety score 49/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. Dividends were paid in 3 separate years. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
2023-01-13$3.602023-01-05—Quarterly
2022-09-21$21.452022-09-06—Quarterly
2015-08-20$896.17——Quarterly

Insider trades

DateInsiderActionSharesPriceValue
2026-08-03Weston ClaireBuy40.00K$6.11244.40K
2026-08-03Kirkby MaxwellBuy40.00K$6.11244.40K
2026-08-01Weston ClaireOther0——
2026-08-01Kirkby MaxwellOther0——
2026-06-18Ye WeiguoSell3.00K$0.752.25K
2026-06-18Ye WeiguoBuy3.00K$0.752.25K
2026-06-18Ye WeiguoSell3.00K$6.3519.05K
2026-06-11Ye WeiguoSell2.80K$0.752.10K
2026-06-11Ye WeiguoBuy2.80K$0.752.10K
2026-06-11Ye WeiguoSell2.80K$6.1717.28K
2026-06-10Carmichael GordonBuy40.00K$5.95238.00K
2026-06-10Epstein David M.Buy40.00K$5.95238.00K
2026-06-10Weng DanBuy40.00K$5.95238.00K
2026-06-10Parry RenateBuy40.00K$5.95238.00K
2026-06-10Zhang PingBuy40.00K$5.95238.00K
2026-06-10Nussbaum Rodney LBuy40.00K$5.95238.00K
2026-06-10Ye WeiguoSell5.00K$0.753.75K
2026-06-10Ye WeiguoBuy5.00K$0.753.75K
2026-06-10Ye WeiguoSell5.00K$6.2431.20K
2026-06-10Ye WeiguoSell6.42K$0.754.81K
2026-06-10Ye WeiguoBuy6.42K$0.754.81K
2026-06-10Ye WeiguoSell6.42K$6.2139.86K
2026-06-09Ye WeiguoSell3.00K$0.752.25K
2026-06-09Ye WeiguoSell3.00K$6.1518.45K
2026-06-09Ye WeiguoSell14.50K$0.7510.88K
2026-06-09Ye WeiguoBuy14.50K$0.7510.88K
2026-06-09Ye WeiguoSell14.50K$6.1489.03K
2026-06-08Bergmann Joshua BenjaminBuy50.00K$6.05302.50K
2026-06-08Luo YingBuy120.00K$6.05726.00K
2026-06-05Ye WeiguoSell15.40K$0.7511.55K
2026-06-05Ye WeiguoBuy15.40K$0.7511.55K
2026-06-05Ye WeiguoSell15.40K$6.4098.57K
2026-06-04Ye WeiguoSell19.57K$0.7514.68K
2026-06-04Ye WeiguoBuy19.57K$0.7514.68K
2026-06-04Ye WeiguoSell19.57K$6.13119.99K
2026-05-26Ye WeiguoSell4.00K$0.753.00K
2026-05-26Ye WeiguoBuy4.00K$0.753.00K
2026-05-26Ye WeiguoSell4.00K$6.1024.40K
2026-05-22Ye WeiguoSell3.50K$0.752.62K
2026-05-22Ye WeiguoBuy3.50K$0.752.62K
2026-05-22Ye WeiguoSell3.50K$6.0821.28K
2026-05-21Ye WeiguoSell12.82K$0.759.62K
2026-05-21Ye WeiguoBuy12.82K$0.759.62K
2026-05-21Ye WeiguoSell12.82K$6.1578.84K
2026-05-20Ye WeiguoSell9.40K$0.757.05K
2026-05-20Ye WeiguoBuy9.40K$0.757.05K
2026-05-19Ye WeiguoSell9.12K$0.756.84K
2026-05-19Ye WeiguoBuy9.12K$0.756.84K
2026-05-19Ye WeiguoSell9.12K$6.3758.09K
2026-05-18Ye WeiguoSell200$0.75150
2026-05-18Ye WeiguoBuy200$0.75150
2026-05-18Ye WeiguoSell200$6.621.32K
2026-05-15Ye WeiguoSell13.10K$0.759.82K
2026-05-15Ye WeiguoBuy13.10K$0.759.82K
2026-05-15Ye WeiguoSell13.10K$6.6587.11K
2026-05-14Zhang PingSell250.00K$10.182.54M
2026-05-14Ye WeiguoSell15.58K$0.7511.69K
2026-05-14Ye WeiguoBuy15.58K$0.7511.69K
2026-05-14Ye WeiguoSell15.58K$6.91107.66K
2026-05-06Luo YingSell10.14K$8.0481.49K
2026-05-05Luo YingSell179$8.011.43K
2026-05-04Bergmann Joshua BenjaminOther47.53K$8.09384.52K
2026-05-04Wang Jialiang (NMN)Other95.06K$0.3230.42K
2026-05-04Wang Jialiang (NMN)Other38.02K$0.9335.36K
2026-05-04Wang Jialiang (NMN)Other42.78K$2.0085.55K
2026-05-04Wang Jialiang (NMN)Other47.53K$5.98284.23K
2026-05-04Xiong YueOther2.38M——
2026-05-04Luo YingOther0——
2026-05-04Luo YingOther475.30K$0.32152.10K
2026-05-04Luo YingOther237.65K$0.93221.01K
2026-05-04Luo YingOther2.26M$0.751.70M
2026-05-04Luo YingOther235.27K$5.981.41M
2026-05-04Luo YingOther988.62K$2.001.98M
2026-05-04GNI Group Ltd.Buy2.14M——
2026-05-04GNI Group Ltd.Buy458.12K——
2026-05-04Eastling Thomas WilsonBuy95.06K$0.3230.42K
2026-05-04Eastling Thomas WilsonBuy95.06K$2.34222.44K
2026-05-04Eastling Thomas WilsonBuy92.68K$5.98554.24K
2026-05-04Eastling Thomas WilsonBuy47.53K$0.9344.20K
2026-05-04Eastling Thomas WilsonBuy33.27K$2.0066.54K
2026-05-04Eastling Thomas WilsonBuy33.27K$0.3210.65K
2026-05-04Eastling Thomas WilsonBuy11.88K$2.0023.76K
2026-01-07Zhang PingBuy100.00K$7.31731.00K
2026-01-07Chen RuoyuBuy50.00K$7.31365.50K
2025-08-18Weng DanBuy52.00K$7.85408.20K
2025-08-18Weng DanOther0——
2025-08-05Zhang PingBuy250.00K$6.921.73M
2025-06-04Eastling Thomas WilsonBuy26.00K$8.58223.08K
2025-06-04Epstein David M.Buy26.00K$8.58223.08K
2025-06-04Nussbaum Rodney LBuy26.00K$8.58223.08K
2025-06-04Parry RenateBuy26.00K$8.58223.08K
2025-06-04Carmichael GordonBuy26.00K$8.58223.08K
2025-05-28Ma SongjiangSell558$10.075.62K
2025-05-27Ma SongjiangSell2.00K$10.2820.56K
2025-05-27Zhang PingBuy250.00K$10.182.54M
2025-05-23Ma SongjiangSell182$10.241.86K
2025-05-22Ma SongjiangSell2.00K$10.9721.94K
2025-05-21Ma SongjiangSell2.00K$10.8321.66K
2025-05-20Ma SongjiangSell2.00K$11.2522.50K
2025-05-19Ma SongjiangSell2.00K$11.1122.22K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 62, holders +7 vs prior quarter. Ownership 9.69%.

HolderSharesChangeChange %Value
HSG HOLDING LTD3.75M3.75MNew24.71M
BLACKROCK, INC.993.94K235.31K+31.02%6.55M
OCTAGON CAPITAL ADVISORS LP954.42K954.42KNew6.29M
VANGUARD CAPITAL MANAGEMENT LLC876.93K-107.28K-10.90%5.78M
GEODE CAPITAL MANAGEMENT, LLC532.95K101.54K+23.54%3.51M
STATE STREET CORP245.40K29.08K+13.44%1.62M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC184.29K19.05K+11.53%1.21M
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.184.29K184.29KNew1.21M
NORTHERN TRUST CORP169.54K35.70K+26.67%1.12M
SBI SECURITIES CO., LTD.166.75K-4.09K-2.39%1.10M
VANGUARD FIDUCIARY TRUST CO151.07K13.39K+9.73%995.57K
VANGUARD PORTFOLIO MANAGEMENT LLC123.95K54.14K+77.55%816.85K
GOLDMAN SACHS GROUP INC86.23K13.11K+17.93%568.29K
BANK OF NEW YORK MELLON CORP62.75K19.61K+45.44%413.52K
MORGAN STANLEY41.69K33.05K+382.48%274.74K
ALLIANCEBERNSTEIN L.P.24.59K2.76K+12.64%171.39K
STRS OHIO25.80K4.70K+22.27%170.02K
DIMENSIONAL FUND ADVISORS LP25.27K00.00%166.52K
NUVEEN, LLC24.50K24.50KNew161.49K
UBS GROUP AG18.76K-2.32K-11.02%123.65K
MILLENNIUM MANAGEMENT LLC18.49K18.49KNew121.84K
DEUTSCHE BANK AG\17.94K7.33K+69.03%118.22K
RHUMBLINE ADVISERS16.86K3.75K+28.58%111.13K
WELLS FARGO & COMPANY/MN16.30K12.01K+279.88%107.40K
PRICE T ROWE ASSOCIATES INC /MD/15.03K15.03KNew100.00K

Earnings and financials

Gyre Therapeutics, Inc. (GYRE) trades at $7.05, with a market cap of $747.97M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Gyre Therapeutics (GYRE) Financials: Revenue & Earnings

GYRE$7.05+0.52 +8.03%

$747.97M

Market Cap

—

P/E

—

Forward P/E

58

Score

Price History